lobbying_activities: 2301504
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2301504 | 64a4424d-470c-410a-9c80-5bdd0d5b3a45 | Q2 | JOHNSON MATTHEY INC. | 401104441 | JOHNSON MATTHEY INC. | 2019 | second_quarter | PHA | H.R. 965 and S. 340 CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895 Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers. | Environmental Protection Agency (EPA),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2019-07-11T12:26:55.100000-04:00 |